Background The interleukin-23 pathway is implicated genetically and biologically in the
pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of …

Background Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and
efficacy as induction therapy in patients with moderately to severely active Crohn's disease …

Background Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in
achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction …

Background There is a great unmet need for new therapeutics with novel mechanisms of
action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that …

Background & Aims: Interleukin-12 and interleukin-23 are inflammatory cytokines implicated
in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 …

Background & Aims MEDI2070 is a human monoclonal antibody that selectively inhibits
interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We …

Objective The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody
secukinumab was safe and effective for the treatment of active Crohn's disease. Design In a …

Background This study assessed the efficacy and safety of briakinumab, a human anti-IL-
12/23p40 monoclonal antibody, compared with placebo for the induction and maintenance …

Abstract Background Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory
cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD) …

Background Intestinal inflammation associated with Crohn's disease is characterized by a
type 1 helper T cell response and elevated levels of interleukin (IL)-12. We report our clinical …